BBOT NASDAQ
BridgeBio Oncology Therapeutics Inc.
1W: -1.1%
1M: -29.4%
3M: -67.3%
YTD: -78.1%
1Y: -75.5%
$2.69
+0.05 (+1.89%)
Pre-Market: $2.90 (+0.21, +7.62%)
Weekly Expected Move ±8.7%
$2
$2
$3
$3
$3
Credit Risk of going bust: lower than 64% of companies Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.8%), BridgeBio Oncology Therapeutics Inc. would be worth roughly what it owes.
Total debt $2.5M against a stock market value of $215.7M.
Distance to default 6.68 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.5M (short-term plus half of long-term), stock volatility 71.5%; Altman Z'' 2.23. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.8%), BridgeBio Oncology Therapeutics Inc. would be worth roughly what it owes.
Total debt $2.5M against a stock market value of $215.7M.
Distance to default 6.68 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.5M (short-term plus half of long-term), stock volatility 71.5%; Altman Z'' 2.23. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2024-02-14
Earliest Filing
2025-03-03
Latest Filing
investor: 2
partner: 2
target: 1
acquirer: 1
Counterparties (Filed by BBOT)
6 relationshipsCompanies named in BBOT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| TheRas, Inc. | BBOT | target | Target company in the business combination agreement to be merged into Helix Acquisition Corp. II. | 2025-03-03 | View |
| Helix II Merger Sub, Inc. | — | acquirer | Wholly-owned subsidiary of Helix Acquisition Corp. II used to effect the merger with TheRas, Inc. | 2025-03-03 | View |
| Cormorant Asset Management, LP | — | investor | Investment advisor and major shareholder providing PIPE investment and support for the business combination. | 2025-03-03 | View |
| Leerink Partners LLC | — | partner | Underwriter for the IPO | 2024-02-14 | View |
| Helix Holdings II LLC | — | investor | Sponsor and private placement investor | 2024-02-14 | View |
| Continental Stock Transfer & Trust Company | — | partner | Trustee for the trust account | 2024-02-14 | View |
Recent 8-K Filings (19)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-08 | Other Events; Exhibits | View | |
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-06-22 | Officer/Director Change; Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-04-29 | Officer/Director Change | View | |
| 2026-04-23 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-26 | Officer/Director Change | View | |
| 2026-03-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-13 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Unregi | Agreement Acquisition | View |
| 2025-08-06 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-04 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-07-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-03-03 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-02-28 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-02-10 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-02-20 | Other Events; Financial Statements and Exhibits | View | |
| 2024-02-14 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR